Narrative Review: Risk-Benefit Hydroxychloroquine and Chloroquine in COVID-19
Chloroquine (CQ) and Hydroxychloroquine (HCQ) are highly prescribed as medications for COVID-19 infection, although no robust or convincing data has yet been published about the efficacy in COVID-19 patients. Therefore, risk and benefit assessment are necessary for decision to prescribe these drugs...
Saved in:
Main Author: | Jarir At Thobari (Author) |
---|---|
Format: | Book |
Published: |
Universitas Gadjah Mada,
2021-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety
by: Michael Takla, et al.
Published: (2020) -
Chloroquine and hydroxychloroquine in the context of COVID-19
by: Ashutosh M Shukla, et al.
Published: (2020) -
Nephrotoxicity of Chloroquine and Hydroxychloroquine in COVID-19 Patients
by: Javad Mahmoudi, et al.
Published: (2021) -
Prophylactic Effect of Chloroquine and Hydroxychloroquine on COVID-19 Treatment
by: Amin Ataie, et al.
Published: (2022) -
Rational use of chloroquine and hydroxychloroquine in times of COVID-19
by: Rosa Camila Lucchetta, et al.
Published: (2020)